Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers

ABSTRACT: The purpose of this study is to determine the safety and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) (or the highest protocol-defined dose level in the absence of establishing an MTD) of ibrutinib in combination with pembrolizumab in participants with advanced, refractory colorectal cancers.

DISEASE(S): Colorectal Carcinoma,Colon Disease,Colon Cancer,Colorectal Cancer,Colorectal Neoplasms,Colonic Diseases

PROVIDER: 2258148 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR